ERBB2 and cancer: In particular, accumulating evidence also indicates that functional crosstalk between HER2 and TGF-β/SMAD signaling results in increased cancer cell proliferation, survival and invasion, accelerated metastasis in animal models, resistance to chemotherapy and HER2-targeted therapy, and the upregulation of BCSCs [22,23].